Cargando…

Long-term survival after a favorable response to anti-EGFR antibody plus chemotherapy to treat bone marrow metastasis: a case report of KRAS-wildtype rectal cancer

Bone marrow metastasis is a rare consequence of colorectal cancer that results in a poor prognosis; few reports describe a favorable response to doublet chemotherapy combined with targeted therapy, which is currently the standard treatment. We experienced a case where anti-epidermal growth factor re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Sho, Fukui, Tadahisa, Suzuki, Shuhei, Takeda, Hiroyuki, Watanabe, Kaname, Yoshioka, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328292/ https://www.ncbi.nlm.nih.gov/pubmed/28260928 http://dx.doi.org/10.2147/OTT.S129275

Ejemplares similares

Rapid Progression of Intracranial Dural Metastases in a Patient with Carcinoma of Unknown Primary Site
por: Takeda, Hiroyuki, et al.
Publicado: (2019)

Distribution and favorable prognostic implication of genomic EGFR alterations in IDH ‐wildtype glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Vimentin-positive and Alpha-fetoprotein-elevated Nuclear Protein of the Testis Midline Carcinoma: A Case Report and Review of the Literature
por: Murano, Chihiro, et al.
Publicado: (2021)

The Role of Cancer Boards in the Treatment Decisions Regarding Chemotherapy
por: Nakamura, Sho, et al.
Publicado: (2016)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer
por: Mayayo-Peralta, Isabel, et al.
Publicado: (2021)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
por: Ma, Xiaoting, et al.
Publicado: (2023)

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
por: Topham, James T., et al.
Publicado: (2022)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Wildtype epidermal growth factor receptor (Egfr) is not required for daily locomotor or masking behavior in mice
por: Roberts, Reade B, et al.
Publicado: (2006)

Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer
por: Xu, Naiqing, et al.
Publicado: (2015)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

Heterogeneity of KRAS Mutation Status in Rectal Cancer
por: Jo, Peter, et al.
Publicado: (2016)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer
por: Xu, Naiqing, et al.
Publicado: (2018)

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
por: Bengala, C, et al.
Publicado: (2010)

Personalization of Chemotherapy for Metastatic Pancreatic Cancer
por: Sasahara, Yuriko (Ito), et al.
Publicado: (2014)

Diameter of Superior Rectal Vein – CT Predictor of KRAS Mutation in Rectal Carcinoma
por: Song, Chenyu, et al.
Publicado: (2020)

CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons: Rapid way to detect EGFR and KRAS mutations
por: Ramteke, Manoj P., et al.
Publicado: (2016)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
por: Chiari, Rita, et al.
Publicado: (2023)

The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis
por: Zhong, Xi, et al.
Publicado: (2020)

Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma
por: Ma, Sirui, et al.
Publicado: (2020)

Characterizing MRI features of rectal cancers with different KRAS status
por: Xu, Yanyan, et al.
Publicado: (2019)

Correlation of EGFR or KRAS mutation status with (18)F-FDG uptake on PET-CT scan in lung adenocarcinoma
por: Takamochi, Kazuya, et al.
Publicado: (2017)

Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR‐mutated non‐small cell lung cancer patient: A case report
por: Zhang, Yiruo, et al.
Publicado: (2020)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype: case series of a new entity
por: Bender, Katja, et al.
Publicado: (2023)

KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix
por: Kim, Jin K., et al.
Publicado: (2021)

Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2021)

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
por: Yang, Wang, et al.
Publicado: (2020)

MPC-02 Prognostic effects of molecular factors in elderly patients with IDH-wildtype Glioblastomas
por: Fukai, Junya, et al.
Publicado: (2020)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
por: von Einem, J. C., et al.
Publicado: (2014)

Long-term stable disease with mFOLFOX6 chemotherapy plus cetuximab for bone marrow metastasis from rectal cancer: A case report
por: Fan, Xiumei, et al.
Publicado: (2023)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
por: Amram, Marie-Laure, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0bjp5tk2ee8k5vpk32gojuaapm